Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vamifeport in adults with transfusion-dependent beta-thalassemia
2021-001639-23Phase 2Terminated
- Sponsor
- CSL Vifor
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vamifeport in beta thalassemia (4 arms), sponsored by CSL Vifor. Primary endpoint: Proportion of subjects achieving transfusion burden reduction response. Started Jul 2021; status: terminated.
02
Drugs
vamifeport
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on 2021-001639-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001639-23.